Estrogen and its receptors in cancer

Medicinal Research Reviews

Volumn 28, Issue 6, 2008, Pages 954-974

  Chen, George G ^a   Zeng, Qiang ^a   Tse, Gary M K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cancer; Estrogen; Estrogen receptor

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GENISTEIN; LETROZOLE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; BREAST CANCER; CANCER GROWTH; DIGESTIVE SYSTEM CANCER; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; REVIEW; THYROID CANCER;

AROMATASE INHIBITORS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; RECEPTORS, ESTROGEN;

EID: 57349130733     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20131     Document Type: Review

References (165)

1. Ascenzi P, Bocedi A, Marino M. Structure-function relationship of estrogen receptor alpha and beta: Impact on human health. Mol Aspects Med 2006;27:299-402.
2. Pearce ST, Jordan VC. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004;50:3-22.
3. Ruggiero RJ, Likis FE. Estrogen: Physiology, pharmacology, and formulations for replacement therapy. J Midwifery Women's Health 2002;47:130-138.
4. Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res 2007;13:4672-4676.
5. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC. Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 2006;21:555-564.
6. Carroll JS, Brown M. Estrogen receptor target gene: An evolving concept. Mol Endocrinol 2006;20:1707-1714.
7. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 2007;67:6477-6483.
8. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-1959.
9. Björnström L, Sjöberg M. Estrogen receptor-dependent activation of AP-1 via non-genomic signalling. Nucl Recept 2004;2:3.
10. Cascio S, Bartella V, Garofalo C, Russo A, Giordano A, Surmacz E. Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem 2007;282:3498-3506.
11. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor G PR30. Annu Rev Physiol 2008;70:165-190.
12. Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids (in press).
13. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146:624-632.
14. Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006;20:1996-2009.
15. Ruff M, Gangloff M, Wurtz JM, Moras D. Estrogen receptor transcription and transactivation: Structurefunction relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Res 2000;2:353-359.
16. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-372.
17. Baumann CK, Castiglione-Gertsch M. Estrogen receptor modulators and down regulators: Optimal use in postmenopausal women with breast cancer. Drugs 2007;67:2335-2353.
18. Jordan VC, O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007;25:5815-5824.
19. Kuiper GG, Lemmen JG, Carlsson B, Corton CJ, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263.
20. Harris HA. Estrogen receptor-beta: Recent lessons from in vivo studies. Mol Endocrinol 2007;21:1-13.
21. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997;2:323-334.
22. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-282.
23. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89-96.
24. Gligorov J, Pritchard K, Goss P. Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. Breast 2007;16(Suppl 3):S1-S9.
25. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer 2006;13:827-837.
26. Flouriot G, Brand H, Denger S, Metivier R, Kos M, Reid G, Sonntag-Buck V, Gannon F. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J 2000;19:4688-4700.
27. Fuqua SA, Wolf DM. Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Res Treat 1995;35:233-241.
28. Price RH Jr, Butler CA, Webb P, Uht R, Kushner P, Handa RJ. A splice variant of estrogen receptor beta missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation. Endocrinology 2001;142:2039-2049.
29. Métivier R, Penot G, Carmouche RP, Hübner MR, Reid G, Denger S, Manu D, Brand H, Kos M, Benes V, Gannon F. Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J 2004;23:3653-3666.
30. Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O. Effects of exon-deleted estrogen receptor beta transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat (in press).
31. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JA. Estrogen receptors: How do they signal and what are their targets. Physiol Rev 2007;87:905-931.
32. Willey SC, Cocilovo C. Screening and follow-up of the patient at high risk for breast cancer. Obstet Gynecol 2007;110:1404-1416.
33. Mourits MJ, De Bock GH. Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk. Int J Gynecol Cancer 2006;16(Suppl 2):494-496.
34. Anonymous. Hormone replacement therapy and cancer. Gynecol Endocrinol 2001;15:453-465.
35. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: A systematic analysis from a network of case-control studies. Int J Cancer 2003;105:408-412.
36. Christov K, Grubbs CJ, Shilkaitis A, Juliana MM, Lubet RA. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. Clin Cancer Res 2007;13:5488-5496.
37. Brodie A, Sabnis G, Jelovac D. Aromatase and breast cancer. J Steroid Biochem Mol Biol 2006;102:97-102.
38. Kutza J, Smith E, Levy B, Jian J, Haugen T, Turek L. Use of hormone replacement therapy (Hrt) And detection of human papillomavirus (Hpv) DNA in postmenopausal women. Ann Epidemiol 2000;10:465-466.
39. Nair HB, Luthra R, Kirma N, Liu YG, Flowers L, Evans D, Tekmal RR. Induction of aromatase expression in cervical carcinomas: Effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Res 2005;65:11164-11173.
40. Fowler JM, Ramirez N, Cohn DE, Kelbick N, Pavelka J, Ben-Shachar I, Morrison C. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: Tissue microarray analysis. Am J Obstet Gynecol 2005;192:1262-1271.
41. Li YF, Hu W, Fu SQ, Li JD, Liu JH, Kavanagh JJ. Aromatase inhibitors in ovarian cancer: Is there a role? Int J Gynecol Cancer (in press).
42. Krasner C. Aromatase inhibitors in gynecologic cancers. J Steroid Biochem Mol Biol 2007;106:76-80.
43. Bulun SE, Chen D, Lu M, Zhao H, Cheng Y, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Su E, Marsh E, Hakim A, Yin P, Ishikawa H, Amin S, Imir G, Gurates B, Attar E, Reierstad S, Innes J, Lin Z. Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 2007;106:81-96.
44. Segawa T, Shozu M, Murakami K, Kasai T, Shinohara K, Nomura K, Ohno S, Inoue M. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res 2005;11:2188-2194.
45. Han WD, Si YL, Zhao YL, Li Q, Wu ZQ, Hao HJ, Song HJ. GC-rich promoter elements maximally confers estrogen-induced transactivation of LRP16 gene through ERalpha/Sp1 interaction in MCF-7 cells. J Steroid Biochem Mol Biol 2008;109:47-56.
46. Meng YG, Han WD, Zhao YL, Huang K, Si YL, Wu ZQ, Mu YM. Induction of the LRP16 gene by estrogen promotes the invasive growth of Ishikawa human endometrial cancer cells through the downregulation of E-cadherin. Cell Res 2007;17:869-880.
47. Vendrell JA, Ghayad S, Ben-Larbi S, Dumontet C, Mechti N, Cohen PA. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007;26:4656-4667.
48. Lin Z, Reierstad S, Huang CC, Bulun SE. Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res 2007;67:5017-5024.
49. Tsai EM, Wang SC, Lee JN, Hung MC. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 2001;61:8390-8392.
50. Treeck O, Diedrich K, Ortmann O. The activation of an extracellular signal-regulated kinase by oestradiol interferes with the effects of trastuzumab on HER2 signalling in endometrial adenocarcinoma cell lines. Eur J Cancer 2003;39:1302-1309.
51. Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, Li XP, Tang JM. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol 2006;99:9-18.
52. Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, Dean DD, Schwartz Z. Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membrane-mediated and inhibited by tamoxifen. Endocrinology 2003;144:1812-1824.
53. Mueck AO, Seeger H. Breast cancer: Are estrogen metabolites carcinogenic? Climacteric 2007;10(Suppl 2):62-65.
54. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1998;58:3197-3201.
55. Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 2008;61:197-203.
56. Au WW, Abdou-Salama S, Al-Hendy A. Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene. Gynecol Oncol 2007;104:276-280.
57. Taylor AH, al-Azzawi F, Pringle JH, Bell SC. Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides. Anticancer Res 2002;22:3993-4003.
58. Boggess JF, Zhou C, Bae-Jump VL, Gehrig PA, Whang YE. Estrogen-receptor-dependent regulation of telomerase activity in human endometrial cancer cell lines. Gynecol Oncol 2006;103:417-424.
59. Zhang Y, Liao Q, Chen C, Yu L, Zhao J. Function of estrogen receptor isoforms alpha and beta in endometrial carcinoma cells. Int J Gynecol Cancer 2006;16:1656-1660.
60. Zhang Y, Liao Q, Chen C, Yu L, Zhao J. Function of estrogen receptor isoforms alpha and beta in endometrial carcinoma cells. Int J Gynecol Cancer 2006;16:1656-1660.
61. Lin CY, Strom A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J, Gustafsson JA, Liu ET. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res 2007;9:R25.
62. Behrens D, Gill JH, Fichtner I. Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells. Mol Cell Endocrinol 2007;274:19-29.
63. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 2007;193:421-433.
64. Treeck O, Pfeiler G, Horn F, Federhofer B, Houlihan H, Vollmer A, Ortmann O. Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Mol Cell Endocrinol 2007;264:50-60.
65. Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett 2006;231:151-157.
66. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-428.
67. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 2004;101:1566-1571.
68. Zhao C, Matthews J, Tujague M, Wan J, Strom A, Toresson G, Lam EW, Cheng G, Gustafsson JA, Dahlman-Wright K. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 2007;67:3955-3962.
69. Macaluso M, Montanari M, Noto PB, Gregorio V, Surmacz E, Giordano A. Nuclear and cytoplasmic interaction of pRb2/p130 and ER-beta in MCF-7 breast cancer cells. Ann Oncol 2006;17(Suppl 7):vii27-vii29.
70. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, Mark M. Effect of single and compound knockouts of estrogen receptors a and b on mouse reproductive phenotypes. Development 2000;127:4277-4291.
71. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC. Estrogen receptor beta protein in human breast cancer: Correlation with clinical tumor parameters. Cancer Res 2003;63:2434-2439.
72. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H. Expression of estrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 2007;37:820-828.
73. Shupnik MA. Estrogen receptor-beta: Why may it influence clinical outcome in estrogen receptor-alpha positive breast cancer? Breast Cancer Res 2007;9:107.
74. Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Eden P, Peterson C, Malmstrom P, Isola J, Borg A, Ferno M. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res 2007;13:1987-1994.
75. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: A clinical correlation. Obstet Gynecol 2008;111:144-151.
76. Chakravarty D, Srinivasan R, Ghosh S, Gopalan S, Rajwanshi A, Majumdar S. Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 2007;17:905-913.
77. Murphy LC, Weitsman GE, Skliris GP, Teh EM, Li L, Peng B, Davie JR, Ung K, Niu YL, Troup S, Tomes L, Watson PH. Potential role of estrogen receptor alpha (ERalpha) phosphorylated at Serine118 in human breast cancer in vivo. J Steroid Biochem Mol Biol 2006;102:139-146.
78. Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest 2007;25:659-665.
79. Davis AM, Ellersieck MR, Grimm KM, Rosenfeld CS. The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Mol Reprod Dev 2006;73:1034-1044.
80. Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M, Negri-Cesi P. Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: Studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 2007;263:46-54.
81. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995;75(S1):338-352.
82. Libutti SK. Understanding the role of gender in the incidence of thyroid cancer. Cancer J 2005;11:104-105.
83. Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J. Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer 2006;6:284-289.
84. Scheiden R, Keipes M, Bock C, Dippel W, Kieffer N, Capesius C. Thyroid cancer in Luxembourg: A national population-based data report (1983-1999). BMC Cancer 2006;6:102-111.
85. Machens A, Hauptmann S, Dralle H. Disparities between male and female patients with thyroid cancers: Sex difference or gender divide? Clin Endocrinol 2006;65:500-505.
86. Ward LS, Assumpcao LV. The impact of gender in differentiated thyroid cancer. Clin Endocrinol 2007;66:752.
87. Ron E, Kleinerman RA, Boice JD Jr, Livolsi VA, Flannery JT, Fraumeni JF. A population-based case-control study of thyroid cancer. J Natl Cancer Inst 1987;79:1-112.
88. Preston-Martin S, Bernstein L, Pike MC, Maldonado AA, Henderson BE. Thyroid cancer among young women related to prior thyroid disease and pregnancy history. Br J Cancer 1987;55:191-195.
89. McTiernan AM, Weiss NS, Daling JR. Incidence of thyroid cancer in women in relation to previous exposure to radiation therapy and history of thyroid disease. J Natl Cancer Inst 1984;73:575-581.
90. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - Long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-332.
91. Fernandez E, La Vecchia C, D'Avanzo B, Negri E. Menstrual and reproductive factors and pancreatic cancer risk in women. Int J Cancer 1995;62:11-14.
92. Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, Walker AM. Anthropometric and reproductive variables and exocrine carcinoma of the pancreas: A population-based case-control study in The Netherlands. Int J Cancer 1992;52:24-29.
93. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005;26:833-876.
94. Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD, Platz EA. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. Clin Endocrinol Metab 2007;92:2519-2525.
95. Thiruvengadam A, Govindarajulu P, Aruldhas MM. Modulatory effect of estradiol and testosterone on the development of N-nitrosodiisopropanolamine induced thyroid tumors in female rats. Endocrine Res 2003;29:43-51.
96. Mori M, Naito M, Watanabe H, Takeichi N, Dohi K, Ito A. Effects of sex difference, gonadectomy, and estrogen on N-methyl-N-nitrosourea induced rat thyroid tumors. Cancer Res 1990;50:7662-7667.
97. Carruba G. Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911.
98. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008;73:233-244.
99. Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 2007;39:183-188.
100. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001;142:2458-2467.
101. Barzon L, Masi G, Pacenti M, Trevisan M, Fallo F, Remo A, Martignoni G, Montanaro D, Pezzi V, Palù G. Expression of aromatase and estrogen receptors in human adrenocortical tumors. Virchows Arch 2008;452:181-191.
102. Konduri S, Schwarz RE. Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens. J Surg Res 2007;140:55-66.
103. Carruba G. Estrogen and prostate cancer: An eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007;102:899-911.
104. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, Risbridger GP. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 2008;22:1512-1520.
105. Dalla Valle L, Ramina A, Vianello S, Fassina A, Belvedere P, Colombo L. Potential for estrogen synthesis and action in human normal and neoplastic thyroid tissues. J Clin Endocrinol Metab 1998;83:3702-3709.
106. Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH, Thelen P. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 2007;6:2626-2633.
107. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008;68:210-222.
108. Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett 2004;566:169-172.
109. Kawabata W, Suzuki T, Moriya T, Fujimori K, Naganuma H, Inoue S, Kinouchi Y, Kameyama K, Takami H, Shimosegawa T, Sasano H. Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Mod Pathol 2003;16:437-444.
110. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA. Estrogen mediates the growth of human thyroid carcinoma cells via an estrogen receptor - ERK pathway. Cell Prolif 2007;40:921-935.
111. Zeng Q, Chen GG, Vlantis AC, Tse GM, van Hasselt CA. Different contributions of estrogen receptor risoforms to the development of thyroid papillary and anaplastic cancers. J Pathol 2008;214:425-433.
112. Cho MA, Lee MK, Nam KH, Chung WY, Park CS, Lee JH, Noh T, Yang WI, Rhee Y, Lim SK, Lee HC, Lee EJ. Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: Different roles in cancer growth and apoptosis. J Endocrinol 2007;195:255-263.
113. Satake M, Sawai H, Go VL, Satake K, Reber HA, Hines OJ, Eibl G. Estrogen receptors in pancreatic tumors. Pancreas 2006;33:119-127.
114. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, Bostwick D, Steiner M. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: Results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006;176:965-970.
115. al-Azzawi F, Wahab M. Estrogen and colon cancer: Current issues. Climacteric 2002;5:3-14.
116. Slattery ML, Ballard-Barbash R, Edwards S, Caan BJ, Potter JD. Body mass index and colon cancer: An evaluation of the modifying effects of estrogen (United States). Cancer Causes Control 2003;14:75-84.
117. al-Azzawi F, Wahab M. Estrogen and colon cancer: Current issues. Climacteric 2002;5:3-14.
118. Newcomb PA, Zheng Y, Chia VM, Morimoto LM, Doria-Rose VP, Templeton A, Thibodeau SN, Potter JD. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res 2007;67:7534-7539.
119. Qiu Y, Langman MJ, Eggo MC. Targets of 17beta-oestradiol-induced apoptosis in colon cancer cells: A mechanism for the protective effects of hormone replacement therapy? J Endocrinol 2004;181:327-337.
120. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003;17:139-147.
121. Burkman RT. Reproductive hormones and cancer: Ovarian and colon cancer. Obstet Gynecol Clin North Am 2002;29:527-540.
122. Gallus S, Bosetti C, Franceschi S, Levi F, Simonato L, Negri E, La Vecchia C. Oesophageal cancer in women: Tobacco, alcohol, nutritional and hormonal factors. Br J Cancer 2001;85:341-345.
123. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: A case-control analysis. Clin Cancer Res 2004;10:113-123.
124. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, Skafar DF, Lonardo F. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 2007;25:5785-5792.
125. Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang CY. Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Mol Cell Biochem 2006;289:101-109.
126. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001;61:632-640.
127. Nakayama Y, Sakamoto H, Satoh K, Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett 2000;161:63-71.
128. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Functional estrogen receptor beta in colon cancer cells. Biochem Biophys Res Commun 1999;261:521-527.
129. Utsumi Y, Nakamura T, Nagasue N, Kubota H, Harada T, Morikawa S. Effect of 17 beta-estradiol on the growth of an estrogen receptor-positive human esophageal carcinoma cell line. Cancer 1991;67:2284-2289.
130. Ueo H, Matsuoka H, Sugimachi K, Kuwano H, Mori M, Akiyoshi T. Inhibitory effects of estrogen on the growth of a human esophageal carcinoma cell line. Cancer Res 1990;50:7212-7215.
131. Liu L, Chirala M, Younes M. Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res 2004;24:2919-2924.
132. Nozoe T, Oyama T, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K. Significance of immunohistochemical expression of estrogen receptors alpha and beta in squamous cell carcinoma of the esophagus. Clin Cancer Res 2007;13:4046-4050.
133. Wang AG, Lee KY, Kim SY, Choi JY, Lee KH, Kim WH, Wang HJ, Kim JM, Park MG, Yeom YI, Kim NS, Yu DY, Lee DS. The expression of estrogen receptors in hepatocellular carcinoma in Korean patients. Yonsei Med J 2006;47:811-816.
134. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000;32:233-238.
135. Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005;70:372-381.
136. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Ogawa J. Combined overexpression of EGFR and estrogen receptor alpha correlates with a poor outcome in lung cancer. Anticancer Res 2005;25:4693-4698.
137. Hershberger PA, Vasquez AC, Kanterewicz B, Land S, Siegfried JM, Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 2005;65:1598-1605.
138. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J. Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin Cancer Res 2005;11:5084-5089.
139. Bentzon N, During M, Rasmussen BB, Mouridsen H, Kroman N. Prognostic effect of estrogen receptor status across age in primary breast cancer. Int J Cancer 2008;122:1089-1094.
140. Arai N, Strom A, Rafter JJ, Gustafsson JA. Estrogen receptor beta mRNA in colon cancer cells: Growth effects of estrogen and genistein. Biochem Biophys Res Commun 2000;270:425-431.
141. Ali SH, O'Donnell AL, Mohamed S, Mousa S, Dandona P. Overexpression of estrogen receptor-alpha in the endometrial carcinoma cell line Ishikawa: Inhibition of growth and angiogenic factors. Gynecol Oncol 2004;95:637-645.
142. Shabani N, Mylonas I, Jeschke U, Thaqi A, Kuhn C, Puchner T, Friese K. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res 2007;27:2027-2033.
143. Waalkes MP, Liu J, Chen H, Xie Y, Achanzar WE, Zhou YS, Cheng ML, Diwan BA. Estrogen signaling in livers of male mice with hepatocellular carcinoma induced by exposure to arsenic in utero. J Natl Cancer Inst 2004;96:466-474.
144. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S. Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex. Clin Cancer Res 2005;11:7280-7287.
145. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN, Ngan HY. Estrogen receptor subtypes in ovarian cancer: a clinical correlation. Obstet Gynecol 2008;111:144-151.
146. Yu S, Wong YC, Wang XH, Ling MT, Ng CF, Chen S, Chan FL. Orphan nuclear receptor estrogen-related receptor-beta suppresses in vitro and in vivo growth of prostate cancer cells via p21(WAF1/CIP1) induction and as a potential therapeutic target in prostate cancer. Oncogene (in press).
147. Arain SA, Shah MH, Meo SA, Jamal Q. Estrogen receptors in human thyroid gland. An immunohistochemical study. Saudi Med J 2003;24:174-178.
148. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS. Estrogen-regulated gene networks in human breast cancer cells: Involvement of E2F1 in the regulation of cell proliferation. Mol Endocrinol 2007;21:2112-2123.
149. Wang Q, Li X, Wang L, Feng YH, Zeng R, Gorodeski G. Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 2004;145:5568-5579.
150. Chen D, Carter TH, Auborn KJ. Apoptosis in cervical cancer cells: Implications for adjunct anti-estrogen therapy for cervical cancer. Anticancer Res 2004;24:2649-2656.
151. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol 1999;71:223-230.
152. Pathirage N, Di Nezza LA, Salmonsen LA, Jobling T, Simpson ER, Clyne CD. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril 2006;86:469-472.
153. Watanabe J, Kamata Y, Seo N, Okayasu I, Kuramoto H. Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J Steroid Biochem Mol Biol 2007;107:163-171.
154. Granata OM, Cocciadiferro L, Miceli V, Polito LM, Campisi I, Carruba G. Metabolic profiles of androgens in malignant human liver cell lines. Ann N Y Acad Sci 2006;1089:262-267.
155. Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ, Goodglick L. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res 2007;67:10484-10490.
156. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, Pietras RJ. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005;65:11287-11291.
157. Ding JX, Feng YJ, Yao LQ, Yu M, Jin HY, Yin LH. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail. Gynecol Oncol 2006;103:623-630.
158. Lee ML, Chen GG, Vlantis AC, Tse GMK, Leung BCH, van Hasselt CA. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J 2005;11:113-121.
159. Lacey JV Jr, Brinton LA, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000;77:149-154.
160. Yasmeen S, Romano PS, Pettinger M, Johnson SR, Hubbell FA, Lane DS, Hendrix SL. Incidence of cervical cytological abnormalities with aging in the women's health initiative: A randomized controlled trial. Obstet Gynecol 2006;108:410-419.
161. Rebbeck TR, Troxel AB, Wang Y, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Bunin G, DeMichele A, Rubin SC, Baumgarten M, Berlin M, Schinnar R, Berlin JA, Strom BL. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 2006;98:1311-1320.
162. Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006;98:1397-1405.
163. Beral V, Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369:1703-1710.
164. Greiser CM, Greiser EM, Dören M. Menopausal hormone therapy and risk
165. Duell EJ, Holly EA. Reproductive and menstrual risk factors for pancreatic cancer: a population-based study of San Francisco Bay Area women. Am J Epidemiol 2005;161:741-747.